David Kabakoff

David Kabakoff joined Sofinnova Ventures as an Executive Partner in 2007. David has 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields.

He currently serves as Chairman of Trius Therapeutics, Chairman of Cebix Inc., and Chairman of Amplimmune, Inc. He is also a Director of InterMune, Inc., and Allylix, Inc. David also serves as a Board Observer at Histogenics..

David co-founded Salmedix, Inc., a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In June 2005, David negotiated the acquisition of Salmedix by Cephalon, Inc.

David also held the positions of Executive Vice President of Dura and President and Chief Executive Officer of Spiros Development Corp. while at Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug delivery company.

Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.

David Kabakoff is the Executive Partner at Sofinnova Investments, based in United States, North America. With a background in Financial Services, David Kabakoff has a rich history of leadership and innovation. David Kabakoff studied Ph.D. unknown @ Yale University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.